Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  West Pharmaceutical Services Inc.    WST

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201420152016201720182019
Sales1 4211 4001 5091 5911 7231 875
EBITDA273280315337406451
Operating profit (EBIT)183190224243297347
Pre-Tax Profit (EBT)------
Net income12795,6144190224264
P/E ratio30,446,344,436,432,127,1
EPS ( $ )1,751,301,912,602,953,49
Dividend per Share ( $ )0,410,460,500,530,570,62
Yield0,77%0,76%0,59%0,56%0,60%0,66%
Reference price ( $ )53.2460.2284.8394.5694.5694.56
Announcement Date02/19/2015
12:00pm
02/18/2016
12:00pm
02/16/2017
12:17pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201420152016201720182019
Debt--25,66,00--
Finance----15,028,0
Operating income (EBITDA)273280315337406451
Leverage
(Debt/EBITDA)
--0,08x0,02x--
Capital Expenditure-132170159158157
Book Value Per Share (BVPS)-14,2 $15,3 $17,4 $19,0 $21,2 $
Cash Flow per Share2,51 $2,88 $2,93 $4,11 $4,51 $4,95 $
Announcement Date02/19/2015
12:00pm
02/18/2016
12:00pm
02/16/2017
12:17pm
---
Balance Sheet Analysis
Assessed data source :
© 2017 Thomson Reuters
Financial Ratios

Size 2017e 2018e
Capitalization 6 998 M$ -
Entreprise Value (EV) 7 004 M$ 6 983 M$
Valuation 2017e 2018e
P/E ratio (Price / EPS) 36,4x 32,1x
Capitalization / Revenue 4,40x 4,06x
EV / Revenue 4,40x 4,05x
EV / EBITDA 20,8x 17,2x
Yield (DPS / Price) 0,56% 0,60%
Price to book (Price / BVPS) 5,45x 4,99x
Profitability 2017e 2018e
Operating Margin (EBIT / Sales) 15,3% 17,3%
operating Leverage (Delta EBIT / Delta Sales) 1,58x 2,70x
Net Margin (Net Profit / Revenue) 11,9% 13,0%
ROA (Net Profit / Asset) 9,70% 10,9%
ROE (Net Profit / Equities) 15,6% 15,5%
Rate of Dividend 20,4% 19,4%
Balance Sheet Analysis 2017e 2018e
CAPEX / CA   9,97% 9,16%
Cash Flow / Sales 19,1% 19,4%
Capital Intensity (Assets / Sales) 1,23x 1,19x
Financial Leverage (Net Debt / EBITDA) 0,02x -0,04x
EPS & Dividend